Claims for Patent: 10,722,508

Summary for Patent: 10,722,508

Title:	Liposomes useful for drug delivery
Abstract:	The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.
Inventor(s):	Hong; Keelung (San Francisco, CA), Drummond; Daryl C. (Lincoln, MA), Kirpotin; Dmitri (Revere, MA)
Assignee:	Ipsen Biopharm Ltd. (GB)
Application Number:	15/896,389
Patent Claims:	1. A liposome composition comprising neutral phospholipid and cholesterol in a mole ratio of 3:2, and N-(methoxy-poly(ethylene glycol)(PEG molecular weight from 500 to 5,000)-oxycarbonyl)-distearoylphosphatidylethanolamine present in an amount between 0.1 and 1 mol % with respect to total liposomal lipids; the liposomes in the composition entrapping irinotecan and sucrose octasulfate, wherein the millimoles of irinotecan per gram of total liposomal lipids is between 0.8 and 1.3. 2. The liposome composition of claim 1, wherein the amount of N-(methoxy-poly(ethylene glycol)(PEG molecular weight from 500 to 5,000)-oxycarbonyl)-distearoylphosphatidylethanolamine is approximately 0.3 mol % with respect to total liposomal lipids. 3. The liposome composition of claim 2, wherein the irinotecan and sucrose octasulfate are entrapped in the form of a gelated or precipitated salt and the neutral phospholipid comprises di stearoylphosphatidylcholine. 4. The liposome composition of claim 1, wherein the liposomes have an average size of about 110 nm as determined by volume-averaged mean of the liposome size distribution by quasi-elastic light scattering (QELS) using Gaussian model. 5. A liposome composition comprising neutral phospholipid and cholesterol in a mole ratio of 3:2, and N-(methoxy-poly(ethylene glycol) (PEG molecular weight from 500 to 5,000)-oxycarbonyl)-distearoylphosphatidylethanolamine present in an amount between 0.1 and 1 mol % with respect to total liposomal lipids; the liposomes in the composition entrapping irinotecan and sucrose octasulfate, wherein the moles of irinotecan per mole of total liposomal lipids is from about 0.15 to about 1.5. 6. The liposome composition of claim 5, wherein the amount of N-(methoxy-poly(ethylene glycol) (PEG molecular weight from 500 to 5,000)-oxycarbonyl)-distearoylphosphatidylethanolamine is approximately 0.3 mol % with respect to total liposomal lipids. 7. The liposome composition of claim 6, wherein the irinotecan and sucrose octasulfate are entrapped in the form of a gelated or precipitated salt and the neutral phospholipid comprises di stearoylphosphatidylcholine. 8. The liposome composition of claim 5, wherein the liposomes have an average size of about 110 nm as determined by volume-averaged mean of the liposome size distribution by quasi-elastic light scattering (QELS) using Gaussian model. 9. A liposome composition comprising neutral phospholipid and cholesterol in a mole ratio of 3:2, and N-(methoxy-poly(ethylene glycol)(PEG molecular weight from 500 to 5,000)-oxycarbonyl)-distearoylphosphatidylethanolamine present in an amount between 0.1 and 0.9 mol % with respect to total liposomal lipids; the liposomes in the composition entrapping irinotecan and sucrose octasulfate, wherein the millimoles of irinotecan per gram of total liposomal lipids is between 0.8 and 1.3. 10. The liposome composition of claim 9, wherein the amount of N-(methoxy-poly(ethylene glycol)(PEG molecular weight from 500 to 5,000)-oxycarbonyl)-distearoylphosphatidylethanolamine is approximately 0.3 mol % with respect to total liposomal lipids. 11. The liposome composition of claim 10, wherein the irinotecan and sucrose octasulfate are entrapped in the form of a gelated or precipitated salt and the neutral phospholipid comprises di stearoylphosphatidylcholine. 12. The liposome composition of claim 9, wherein the liposomes have an average size of about 110 nm as determined by volume-averaged mean of the liposome size distribution by quasi-elastic light scattering (QELS) using Gaussian model.